What You to Need to Know:
IBM Watson Health and EBSCO Health Resources will announce the merging of their respective platforms – DynaMed and IBM Micromedex – into a single, high-value global solution called DynaMed and Micromedex with Watson.
By combining the real-world evidence available on these platforms, with AI and natural language processing, this new solution will enable care providers to easily access information to inform both diagnostic and operational decisions.
IBM Watson Health and EBSCO Information Services (EBSCO) announced a strategic partnership aimed towards enhancing clinical decision support (CDS) and operations for healthcare providers and health systems. The companies are combining their respective platforms – DynaMed® and IBM Micromedex® – into a single, high-value solution called DynaMed and Micromedex with Watson. The combined solution is designed to bring together drug and disease content, into a single search for evidence-based insights to help inform clinical decisions.
DynaMed’s Peer-Reviewed Clinical Content
DynaMed provides peer-reviewed clinical content including systematic literature reviews in 28 specialties for comprehensive disease topics, health conditions, and abnormal findings to highly focused topics on evaluation, differential diagnosis, and management. The content undergoes a rigorous, seven-step process, giving clinicians access to current, evidence-based diagnostic and therapeutic recommendations. IBM Micromedex is one of the largest online reference databases for medication information. It is used by more than 4,500 hospitals and health systems worldwide for decision-making in medication therapy management, disease and condition management, toxicology, alternative medicine, and patient education.
Direct Access to Drug & Disease Content at Point of Care
By combining the real-world evidence available on these platforms, with AI and natural language processing, this new solution will enable care providers to easily access information to inform both diagnostic and operational decisions. The platform’s cloud-based technology gives clinicians direct access to content in real-time so they can make more informed decisions at the point of care – ultimately improving patient outcomes. This new technology is available from any workplace or device and connects with the patient’s electronic health record (EHRs).
DynaMed and Micromedex with Watson is expected to be available for general adoption in Spring, 2020. IBM and EBSCO will also continue to sell the IBM Micromedex and DynaMed® solutions separately in order to offer flexible options to help meet customers’ needs.